dimarts, 16 d’abril del 2019

Johnson & Johnson shares rise on Street-beating Q1, lifted guidance

Johnson & Johnson

Shares in Johnson & Johnson (NYSE:JNJ) have risen today after the medical giant posted first quarter earnings that topped expectations on Wall Street and lifted its EPS guidance for the full fiscal year.

The New Brunswick, N.J.-based company posted profits of approximately $3.75 billion, or $1.39 per share, on sales of $20 billion for the three months ended March 31, seeing the bottom line shrink 14.2% while sales grew 0.1% compared with the same period during the previous year.

Adjusted to exclude one-time items, earnings per share were $2.10, ahead of the $2.04 consensus on Wall Street where analysts expected to see sales of $19.6 billion, which the company also topped.

“Our strong first-quarter results reflect continued underlying operational sales and adjusted EPS growth. At the same time, we remain focused on investing in innovative technologies and platforms that will make a meaningful difference in the lives of patients around the world. I am proud of our global colleagues’ collective efforts to deliver on our long-term goals and our ability to create value for all of our stakeholders,” chair & CEO Alex Gorsky said in a press release.

Johnson & Johnson lifted its guidance for the remaining fiscal year, now expecting to see adjusted diluted EPS of between $8.53 and $8.63 up from previous guidance of between $8.50 and $8.65. The company maintains its sales expectation of between $80.4 billion and $81.2 billion.

Shares in Johnson & Johnson have risen 2.6% so far today, at $140.08 as of 9:47 a.m. EDT.

Earlier this month, Johnson & Johnson said that its  its Ethicon biz completed its $3.4 billion acquisition of robotic surgery dev Auris Health and the $2.8 billion divestiture of its Advanced Sterilization Products to Fortive (NTSE:FTV).



from MassDevice http://bit.ly/2XhKmSy

1 comentari:

  1. Existing technology such as RIS and PACS are seriously outdated technologies that are among the contributing factors. Moreover, they cost a lot and is not designed to get more referrals.

    Furthermore, RIS, PACS, Enterprise Imaging (VNA and Image Sharing) are unsuitable for AI and 3D/VR/AR.

    LifeVoxel.AI platform offers a better alternative for the medical imaging community. Its unique approach is based on 12 international patents that encompass visualization, AI, image management, workflow and billing. It works 100X faster and 50%+ cheaper than all our competitors.

    RIS PACS
    RIS PACS Software

    ResponElimina